Brought to you by 
Prometheus gets US Lotronex rights from GSK
01 Jun 2011
Executive Summary
Prometheus (therapeutics and diagnostics for gastrointestinal, autoimmune, and inflammatory diseases) has licensed exclusive US marketing rights to GlaxoSmithKline's controversial irritable bowel syndrome drug Lotronex (alosetron).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Prometheus gets US Lotronex rights from GSK
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice